$19.5 Billion USD
The APEX Strategy
Drug Asset Optimization
Early Access Program
Directors and Officers
Tyler PowellChief Executive Officer & Director
Tyler Powell is an experienced entrepreneur with over 15 years of experience in the financial services sector. As a leader, Tyler identifies areas with substantial unmet need and builds collaborative teams with diverse experience that believe in the mission.
Tyler has deep expertise in venture capital, initial public offerings, secondary financings, mergers and acquisitions, public vehicles, and operations as well as in media and investor relations. While running a financial services consulting company for a decade, Tyler supported promising companies with infusions of capital, management and restructuring to maximize the value of their core business.
Connect with Tyler on LinkedIn here.
Arron VictoryChief Strategy Officer & Director
Arron Victory is a purpose-built entrepreneur, corporate strategy leader, Canadian Armed Forces Veteran and advocate with robust experience in health care, emerging therapeutics, and community engagement.
Arron is also an Ambassador for Veteran advocacy group, Wounded Warriors Canada, Board Member of the Heroic Hearts Project, a charity providing access to psychedelic therapies for Veterans, and an Advisory Board Member for the Chronic Pain Centre of Excellence, a research centre improving the understanding of Veteran-specific chronic pain and how best to manage it.
Connect with Arron on LinkedIn here.
Orion LekosChief Science Officer & Director
Dr. Lekos is an industry-leading green entrepreneur and engineer, specializing in the extraction of valuable phytochemicals from plants, renewable energy, water, biomass derived chemicals, and micro-organisms.
With a PhD in Bioengineering and a master’s degree in environmental chemistry, Dr. Lekos has led global clinical trials while being instrumental in the development & design of the extractions and formulations for a top three global cannabis company. He also served as the Chief Science Officer of a biotechnology company developing poppy genetics to produce non-addictive opiate alkaloids.
Dr. Lekos also has robust experience in Technology Commercialization, Environmental Management, Life Cycle Analysis, Industrial Plant Design, Plant Commissioning, Green Chemical Design, and Good Manufacturing Practices.
Connect with Dr. Lekos on LinkedIn here.
Raashid is the Senior Director of Medical Cannabis at Shoppers Drug Mart, Canada’s largest pharmacy chain. He currently heads all aspects of the medical cannabis business unit, previously holding roles in eHealth, Pharmacy Operations and Business Development at the company, helping spearhead a new pharmacy dispensing system that is currently implemented across the enterprise.
Prior to joining Shoppers Drug Mart, Raashid worked in the pharmaceutical industry at Janssen Ortho in Sales Analytics and at Eli Lilly Canada in Government and Economic Affairs. Raashid holds a pharmacy degree from the University of Toronto and is a licensed pharmacist.
Dr. Rampakakis has over 20 years of experience in scientific research, has contributed to the conception, design, analysis and interpretation of more than 100 large scale, national and international, pre-approval and observational studies, and has contributed to 8 market approvals. He is an adjunct member of the department of pediatrics of McGill University and an author on over 100 peer-reviewed publications and over 300 presentations at international conferences.
Dr. Rampakakis received his Ph.D. from the Department of Biochemistry in McGill University and the McGill Cancer Centre, and obtained post-doctoral training in Pharmacoepidemiology at McGill University and the Jewish General Hospital.
Dr. Kevin Lutz is a Registered Psychologist in BC, with more than 20 years of clinical experience in a variety of areas ranging from addictions to general mental health to forensic psychiatry. Since 2014 Dr. Lutz has focused his practice toward individual trauma treatment and the facilitation of educational and treatment group programs for trauma and PTSD clinically. Dr. Lutz has also participated in clinical research as a sub-investigator and therapist examining the effectiveness of psychedelics to support mental health since 2015, and since 2022 as a trainer internationally to therapists from around the world who are interested in delivering psychedelic psychotherapy. Currently much of Dr. Lutz’s work is dedicated to supporting military and first responder populations.
Franklin King MD is a psychiatrist at the Massachusetts General Hospital and an Instructor in Psychiatry at Harvard Medical School. He is a graduate of the University of Massachusetts Medical School, after which he completed residency in adult psychiatry at the MGH/McLean program, followed by a fellowship in Consult Liaison Psychiatry and a research fellowship at the Cardiac Psychiatry Research Center.
Dr. King is currently the Director of Training and Education at the MGH Center for Neuroscience of Psychedelics. He is actively involved in research into psychedelic-assisted therapies, and in addition practices clinically at MGH.